Role of Intravitreal Bevacizumab on Ischaemic and non Ischaemic Central Retinal Vein Occlusion and a Comparison
Annals of International medical and Dental Research
To evaluate the effect of intravitreal bevacizumab on macular edema in diagnosed cases of ischaemic and non ischaemic central retinal vein occlusion. Methods: In a prospective study conducted between April 2016 to March 2017, 34 diagnosed cases of ischaemic CRVO and 42 diagnosed cases of non ischaemic CRVO with macular edema (macular thickness >350 micometer) were assessed for best corrected visual acuity, macular thickness by OCT, fluorosceine angiography and tonometry. Each of the patients
... of the patients were given intravitreal bevacizumab (1.25 mg in 0.05 ml total volume) thrice at interval of 4 weeks and follow up was done at 1 ,2 and 6 months following last injection. Results: The mean macular thickness decreased significantly in both ischaemic and non ischaemic CRVO following intravitreal bevacizumab and the mean BCVA improved (log Mar). Conclusion: Intravitreal bevacizumab is the mainstay for macular edema following CRVO. Decrease in macular thickness in non-ischemic CRVO is faster and more constant compared to ischemic CRVO. Ischaemic CRVO is more resistant to intravitreal bevacizumab, needs more number and frequency of injections. Intravitreal steroid for better response and more closer follow ups with frequent interventions were needed.